Osteoblast Response to Commercially Available Ti-6Al-4V and Novel Porous Tantalum. In Vitro Biocompatibility Studies

The response of human osteoblasts to materials is crucial for evaluating biocompatibility of an implant material for bone defects. Previous work in our lab demonstrated that the response of human osteoblasts to orthopaedic and dental materials in vitro varies depending on the sex and age of the patient [1]. Osteoblasts from female patients older than 60 years old, adhered less and produced less matrix proteins and calcification than osteoblasts from younger female patients and all ages of male patients. Recently developed, porous tantalum demonstrates improved biomechanical properties for bone and good biocompatibility in in vivo human studies, however there are few, if any, in vitro biocompatibility studies on this material. In this project, we aimed to compare the phenotypic expression of human osteoblasts from young and old female patients to commercially available Ti-6Al-4V and porous tantalum in a well-developed in vitro system. 1. Zhang H, Lewis CG, Aronow MS, Gronowicz G. The effect of patient age on human osteoblasts’ response to Ti-6Al-4V implants in vitro. J. Orthop. Res. 2004;22(1):30-8.

METALLOTHIONEIN RECEPTOR EXPRESSION IN LEUKOCYTES

Metallothionein (MT) represents a family of low molecular weight, cysteine-rich proteins that play a number of roles in cellular homeostasis. MT is synthesized as a consequence of a variety of cellular stressors, including exposure to toxic metals, increased temperature, tissue wounding, as well as inflammatory and tumorigenic agents. This protein has been found in both intracellular compartments and extracellular spaces, and its function may depend in part on its location. Extracellular MT is able to redistribute heavy metals between tissues, act as a powerful antioxidant, affect cell proliferation, and cause the suppression of T-dependent humoral immunity. The nature of the interaction of MT with the plasma cell membrane has yet to be characterized, despite many observations that there is a significant pool of extracellular MT, and that this extracellular MT will bind to leukocyte plasma membranes. In light of studies that MT can be detected on the surface of leukocytes from animals immunized in the presence of adjuvant, and that an MT specific receptor has been found on the surface of astrocytes, we have investigated the nature of the potential MT-specific surface receptor-binding site(s) on the plasma membrane of leukocytes. The identification of MT-receptors will allow for the characterization of the mechanism MT uses for immunomodulation, for the manipulation of MT in its immunomodulatory role, and for the identification of patients at higher risk for those potentially harmful immunomodulatory effects.